Medicaid cracks down on hidden PBM markups, mandates transparent drug pricing

What it does

This bill requires the federal government to conduct monthly surveys of pharmacy drug prices to establish accurate reimbursement benchmarks for Medicaid, and mandates that pharmacy benefit managers (PBMs) and managed care entities use transparent "pass-through" pricing—paying pharmacies only for the actual drug cost plus a fair dispensing fee, with no hidden markups. Pharmacies that refuse to report prices face penalties up to $100,000 per violation; PBMs that pocket the difference between what they charge the state and what they pay pharmacies are barred from claiming federal matching funds.

Why we flagged it

The bill's core mechanism is dual: (1) establishing federal price-survey benchmarks to ensure accurate Medicaid reimbursement to pharmacies, and (2) prohibiting PBMs and managed care entities from extracting hidden markups (spread pricing) between what they charge the state and what they pay pharmacies. Both are regulatory constraints on intermediaries, not subsidies or deregulation.

What the text implies

• The 18-month delayed application to non-retail (mail-order, specialty) pharmacies may allow PBMs time to restructure contracts before transparency rules apply, potentially limiting the bill's reach into high-margin specialty drug channels.
• The exemption from Administrative Procedure Act notice-and-comment rulemaking (section 2(e) and 3(d)) allows HHS to implement pricing benchmarks and PBM rules by program instruction alone, bypassing public input on methodology—a significant delegation of standard-setting authority.
• The $5M appropriation for HHS Inspector General oversight of survey data is modest relative to the scope of national pharmacy pricing surveillance; underfunding may limit detection of affiliate-pricing abuse and related-party transactions.
• Covered entities (hospitals, FQHCs, etc.) purchasing drugs under the 340B program may report excess ingredient costs above actual acquisition cost, but the bill does not restrict their ability to pocket the difference—creating a potential loophole for 340B entities to extract spread-like margins.
• States retain discretion to set dispensing fees; the bill only requires that PBM fees match or exceed the state's direct-pay rate, leaving room for states to set low baseline fees that PBMs then match, potentially suppressing pharmacy margins across the board.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and Medicaid beneficiaries gain from more accurate pharmacy reimbursement (reducing incentives for pharmacy closures in underserved areas), transparent pricing (reducing hidden PBM markups that inflate Medicaid costs), and lower overall drug costs passed through to the program. States and the federal government reduce waste from spread pricing. The compliance burden on pharmacies is offset by fairer payment and the public disclosure of pricing data.

Who stands to gain

• Medicaid programs (reduced spread-pricing waste)
• Community pharmacies (more accurate reimbursement, reduced PBM margin extraction)
• Medicaid beneficiaries (lower effective drug costs)

Named in the bill

Department of Health and Human Services (HHS), HHS Office of Inspector General, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs), Retail community pharmacies, Non-retail pharmacies (mail-order, specialty), Medicaid State Agencies, Covered entities (340B program participants), Wholesalers and drug distributors

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Mar 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 11, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

9 lobbying clients named this bill on 12 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $12,180,656 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 89% of bills with at least one filing.

Peter Welch, the sponsor, reported $44,000 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $6,472,656 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• Food Marketplace Inc — $1,384,000 on 2 filings
• National Association of Chain Drug Stores — $290,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.